FindTrial
Sign In

SODIUM BICARBONATE AND CHRONIC KIDNEY DISEASE PROGRESSION

A SINGLE-CENTER,PROSPECTIVE , RANDOMIZED, PARALLEL GROUP STUDY ON ROLE OF SODIUM BICARBONATE THERAPY IN RETARDING CHRONIC KIDNEY DISEASE PROGRESSION - SOBIRC

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/039964
Enrollment
100
Registered
2022-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 2: N184- Chronic kidney disease, stage 4 (severe)

Interventions

Intervention1: SODIUM BICARBONATE AND STANDARD OF CARE: SODIUM BICARBONATE 500MG BD/TDS FOR 12 MONTHS Control Intervention1: STANDARD OF CARE: STANDARD OF CARE

Sponsors

INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH KOLKATA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: CKD STAGE 3 AND 4 SERUM BICARBONATE LESS THAN 22 MMOL/L STABLE CLINICAL CONDITION AS ASSESSED BY TREATING PHYSICIAN

Exclusion criteria

Exclusion criteria: MALIGNANCY MORBID OBESITY COGNITIVE IMPAIRMENT SEPSIS POORLY CONTROLLED BLOOD PRESSURE OVERT CONGESTIVE HEART FAILURE AUTOIMMUNE DISEASE LIMB AMPUTATION POLYCYSTIC KIDNEY DISEASE

Design outcomes

Primary

MeasureTime frame
PROPORTION OF PATIENTS HAVING EGFR DECLINE MORE THAN 5 ML/MIN OR END STAGE KIDNEY DISEASETimepoint: 12 MONTHS—

Secondary

MeasureTime frame
CHANGES IN NUTRITIONAL STATUS PROPORTION OF PATIENTS WITH ADVERSE EVENTSTimepoint: 12MONTHS—

Countries

India

Contacts

Public ContactRAJARSHI DATTA

IPGME&R KOLKATA

lahiri.arpi@gmail.com9433254601

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026